Research use only. This article is written for licensed researchers and educational reference. Retatrutide and cagrilintide are investigational/research compounds in Canada and are not approved for human or animal use.
For most of the last two years, “which GLP-1 compound is winning” has really meant one comparison: retatrutide vs semaglutide. We’ve covered that match-up in detail elsewhere, including the full TRIUMPH-1 Phase 3 dataset. But that framing is getting dated. Novo Nordisk’s cagrilintide-based combination, CagriSema, is now sitting at the FDA with real Phase 3 numbers behind it, and at least six other compounds are running active Phase 3 programs of their own. Anyone building a comparative research protocol around a single reference compound is working with less context than the field actually offers right now.
This piece is deliberately narrow in one place and wide in another: a close look at how retatrutide’s newest data actually stacks up against cagrilintide/CagriSema specifically, followed by a fast tour of everything else in the 2026 pipeline that a research program should probably have on its radar.
Retatrutide vs. Cagrilintide: Two Different Bets, Not Two Versions of the Same Drug
It’s worth being precise about what’s being compared, because retatrutide and cagrilintide aren’t playing the same game mechanistically. Retatrutide is a single peptide engaging three receptors at once — GLP-1, GIP, and glucagon. Cagrilintide, on its own, is an amylin analogue and not a weight-loss heavyweight by itself. The molecule that actually matters commercially is CagriSema, Novo Nordisk’s fixed-dose combination of cagrilintide with semaglutide. So the meaningful comparison is a triple agonist against a dual-mechanism combination product, not peptide-for-peptide.
On efficacy, the current numbers favor retatrutide. Our TRIUMPH-1 breakdown covers the full dataset, but the short version: retatrutide 12 mg produced 28.3% average weight loss at 80 weeks, reaching 30.3% by week 104 in higher-BMI participants. CagriSema’s REDEFINE-1 trial, by comparison, reported 22.7% mean weight loss at 68 weeks — genuinely strong, and better than semaglutide alone, but still below retatrutide’s range at a comparable timepoint. Novo Nordisk’s own chief scientific officer put it fairly at this year’s ADA meeting, calling the comparison a “jury still out” situation while more CagriSema data continues to accumulate. Novo has since announced a higher-dose CagriSema program (2.4 mg/7.2 mg) starting later in 2026 — effectively tripling the cagrilintide component, which reads as a fairly direct acknowledgment that the efficacy gap exists.
Where amylin-based combinations may have an edge is tolerability, and that’s a genuinely open research question rather than a settled one. Amylin agonism works through a different satiety pathway than glucagon receptor activation, and some groups studying retatrutide’s dysesthesia and heart-rate signal (both tied to its glucagon receptor activity) are curious whether cagrilintide-based combinations sidestep those specific effects while still working through GLP-1 for the appetite side. Nobody has run that comparative safety study directly yet.
Timeline is the other axis worth tracking, and it cuts the other way. CagriSema was submitted to the FDA in December 2025, with a decision expected in Q4 2026 or Q1 2027 — a possible launch by mid-2027. Retatrutide is behind on paperwork: Lilly still hadn’t filed its NDA as of mid-2026. Realistic estimates put that submission in Q4 2026, a decision in late 2027, and commercial availability more likely in early 2028. So even with better topline numbers right now, retatrutide could plausibly reach the market a full year after CagriSema.
The Rest of the Pipeline Isn’t Standing Still
Retatrutide and CagriSema get most of the attention, but at least six other Phase 3 programs are active in 2026, and each is worth knowing by name:
Orforglipron already crossed the finish line — FDA approved in April 2026 under the brand name Foundayo, the first small-molecule, non-peptide oral GLP-1 agonist. It won’t touch a triple agonist’s weight-loss ceiling, but a once-daily pill with no food or water timing restrictions changes who’s willing to start treatment in the first place, which matters for a different reason than raw efficacy.
Survodutide, a GLP-1/glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma, is furthest along behind the two leaders and is being pushed hard for MASH (liver disease) as well as obesity indications.
Mazdutide, another GLP-1/glucagon dual agonist, gets its first real head-to-head against semaglutide from the DREAMS-3 readout at ADA 2026 — one of the more informative comparisons this year, since it isolates what the glucagon receptor is actually contributing on its own.
Amycretin — increasingly referred to by its official name, zenagamtide, in Novo’s own materials — pairs GLP-1 with amylin agonism in both injectable and oral formats. Early data has people calling it a candidate for the highest-efficacy obesity compound tested so far, though Phase 3 confirmation is still pending.
MariTide (Amgen) and VK2735 (Viking Therapeutics) round out the group. MariTide posted up to 20% weight loss in Phase 2 without diabetes and 17% with it, with its Phase 3 VELOCITY program still in planning. VK2735’s Phase 2 VENTURE trial showed 14.7% at the 15 mg dose over just 13 weeks, and its Phase 3 VANQUISH trial has finished enrollment, with results not yet public.
None of this diminishes retatrutide — it remains the efficacy leader among everything with real Phase 3 numbers behind it. But “what comes after retatrutide” is no longer a short list, and a research design built around a single compound’s mechanism is missing a lot of the field’s current context.
Why the Comparison Matters More Than the Compound
The practical implication for research design is that single-compound protocols are getting harder to justify without a comparator arm. The differences between a triple agonist, a GLP-1/glucagon dual agonist, and an amylin-GLP-1 combination aren’t subtle — they show up in the side-effect profile as much as in the topline efficacy number. Retatrutide’s TRIUMPH-1 discontinuation rate (11.3% at 12 mg) ran meaningfully higher than tirzepatide’s (~6.2%) or semaglutide’s (~7.3%), which is exactly the kind of mechanism-specific tolerability question that only becomes visible once you’re studying more than one compound side by side. Whether an amylin-based combination changes that picture is still an open question, and it’s one a single-compound program simply can’t answer.
That’s the direction our own catalogue has been heading. Panda Peptide carries both research-grade Retatrutide and Cagrilintide, each third-party HPLC-verified at ≥99% purity, for exactly this kind of comparative work.
For Canadian teams sourcing either compound, Anglo Peptides also supplies research-grade Retatrutide with per-batch third-party purity testing and domestic shipping.
Frequently Asked Questions
Is cagrilintide the same thing as CagriSema?
No. Cagrilintide is a standalone amylin analogue. CagriSema is Novo Nordisk’s fixed-dose combination of cagrilintide with semaglutide, and it’s the combination — not cagrilintide alone — that produces the headline weight-loss numbers researchers are comparing against retatrutide.
Which will reach market first, retatrutide or CagriSema?
CagriSema has the timeline advantage. It was submitted to the FDA in December 2025, with a decision plausible by Q4 2026 or Q1 2027. Retatrutide’s NDA wasn’t filed as of mid-2026, putting its likely approval in late 2027 and commercial availability closer to early 2028.
Is there a direct head-to-head trial between retatrutide and cagrilintide/CagriSema?
No. As with most cross-molecule comparisons in this class, everything currently available is an indirect, cross-trial comparison — different populations, different trial designs, different durations. Treat any side-by-side numbers as directional, not definitive.
What’s the most efficient compound in the current pipeline?
By topline Phase 3 numbers, retatrutide still leads. But amycretin/zenagamtide’s early data is being watched closely as a potential new ceiling, and Phase 3 confirmation for that compound is still pending.
Related Research
- Retatrutide Canada — Complete Research Guide
- Retatrutide vs Semaglutide: 2026 Phase 3 Meta-Analysis
- Tirzepatide vs Semaglutide vs Retatrutide: How the Three Compare
References
- Jastreboff AM, et al. “Triple-hormone-receptor agonist retatrutide for obesity.” N Engl J Med. 2023;389(6):514–526.
- Eli Lilly and Company. TRIUMPH-1 Topline Results. Press release, May 21, 2026.
- Novo Nordisk. REDEFINE-1 CagriSema Topline Results, 2025–2026.
- “ADA: Novo CSO says ‘jury still out’ on CagriSema v. retatrutide” — Fierce Biotech
Disclaimer: This article is for educational and research reference only. Retatrutide and cagrilintide are supplied strictly for in-vitro laboratory research and are not for human or animal consumption. Nothing here constitutes medical advice.